{'52WeekChange': 1.0243292,
 'SandP52WeekChange': 0.0644362,
 'address1': '675 West Kendall Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 158.51,
 'askSize': 800,
 'averageDailyVolume10Day': 505850,
 'averageVolume': 815353,
 'averageVolume10days': 505850,
 'beta': 1.85042,
 'beta3Year': None,
 'bid': 142,
 'bidSize': 900,
 'bookValue': 11.927,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 153.47,
 'dayLow': 148.59,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -17.6,
 'enterpriseToRevenue': 57.851,
 'enterpriseValue': 16541433856,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '617 551 8101',
 'fiftyDayAverage': 148.11029,
 'fiftyTwoWeekHigh': 167.33,
 'fiftyTwoWeekLow': 69.11,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 113866152,
 'forwardEps': -4.49,
 'forwardPE': -34.098,
 'fromCurrency': None,
 'fullTimeEmployees': 1323,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.00801,
 'heldPercentInstitutions': 0.94741,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/alnylam.com',
 'longBusinessSummary': 'Alnylam Pharmaceuticals, Inc., a biopharmaceutical '
                        'company, focuses on discovering, developing, and '
                        'commercializing RNA interference (RNAi) therapeutics. '
                        "The company's pipeline of investigational RNAi "
                        'therapeutics focus on genetic medicines, '
                        'cardio-metabolic diseases, hepatic infectious '
                        'diseases, and central nervous system/ocular diseases. '
                        'Its marketed products include ONPATTRO (patisiran), a '
                        'lipid complex injection for the treatment of the '
                        'polyneuropathy of hereditary transthyretin-mediated '
                        'amyloidosis in adults; and GIVLAARI for the treatment '
                        'of adults with acute hepatic porphyria (AHP). In '
                        'addition, the company is developing givosiran for the '
                        'treatment of patients with AHP; lumasiran for the '
                        'treatment of primary hyperoxaluria type 1, or PH1; '
                        'patisiran for the treatment of transthyretin '
                        'amyloidosis, or ATTR amyloidosis, with '
                        'cardiomyopathy; and vutrisiran for the treatment of '
                        'ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has '
                        'strategic alliances primarily with Sanofi Genzyme; '
                        'The Medicines Company; Ionis Pharmaceuticals, Inc.; '
                        'and Regeneron Pharmaceuticals, Inc., as well as '
                        'collaboration with Vir Biotechnology, Inc. to advance '
                        'RNAi therapeutics for the treatment of coronavirus '
                        'infection, including COVID-19. It also has a '
                        'collaboration and license agreement with Dicerna '
                        'Pharmaceuticals, Inc. to develop and commercialize '
                        'investigational ribonucleic acid interference '
                        'therapeutics for the treatment of alpha-1 antitrypsin '
                        'deficiency-associated liver disease, as well as Vir '
                        'Biotechnology, Inc. to develop and commercialize RNAi '
                        'therapeutics. The company was founded in 2002 and is '
                        'headquartered in Cambridge, Massachusetts.',
 'longName': 'Alnylam Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 17578788864,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_2796659',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -886422016,
 'nextFiscalYearEnd': 1640908800,
 'open': 152.41,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.53,
 'phone': '617 551 8200',
 'previousClose': 154.61,
 'priceHint': 2,
 'priceToBook': 12.836422,
 'priceToSalesTrailing12Months': 61.478912,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 153.47,
 'regularMarketDayLow': 148.59,
 'regularMarketOpen': 152.41,
 'regularMarketPreviousClose': 154.61,
 'regularMarketPrice': 152.41,
 'regularMarketVolume': 226760,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 114819000,
 'sharesPercentSharesOut': 0.047399998,
 'sharesShort': 5439744,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 5234769,
 'shortName': 'Alnylam Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.0656,
 'shortRatio': 5.68,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'ALNY',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -7.979,
 'twoHundredDayAverage': 129.25562,
 'volume': 226760,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.alnylam.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02142'}